Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple SclerosisNot Yet Recruiting
NCT07749157Phase 1Updated Aug 6, 2026
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruiting
NCT06862869N/AUpdated Aug 6, 2026
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
China
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Not Yet Recruiting
NCT07503340Phase 2Updated Aug 6, 2026
Sponsor: Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRecruiting
NCT07170150Phase 3Updated Aug 6, 2026
Sponsor: Hoffmann-La Roche
Alzheimers Disease
United States, Argentina, Australia, Brazil, Canada +11 more
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruiting
NCT06790693Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Brazil, Canada +15 more
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaActive Not Recruiting
NCT03157635Phase 1, Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Paroxysmal Hemoglobinuria, Nocturnal
France, Germany, Hungary, Italy, Japan +2 more
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruiting
NCT05039619Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Lupus Nephritis
United States, Brazil, Canada, France, Italy +7 more
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Recruiting
NCT06065748Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
United States, Argentina, Australia, Austria, Belgium +32 more
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruiting
NCT05583617Phase 1, Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Multiple Myeloma
Australia, France, Germany, Poland, South Korea +1 more
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruiting
NCT06084936Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Lymphoma
United States, Australia, Brazil, Canada, China +8 more
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaActive Not Recruiting
NCT05171647Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Non-Hodgkin Lymphoma
United States, Argentina, Brazil, Canada, China +8 more
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive Not Recruiting
NCT04589845Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Australia, Belgium, Brazil, Canada +18 more
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesNot Yet Recruiting
NCT07748208Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer · Diabetes Type II
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsRecruiting
NCT06982131Phase 1Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Overweight · Obesity
Netherlands
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruiting
NCT07287150Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer
United States, Australia, Brazil, Canada, France +7 more
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruiting
NCT05091424Phase 1Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
United States, Australia, China, France, Germany +5 more
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active Not Recruiting
NCT05170204Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Australia, Belgium, Brazil, Chile +14 more
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruiting
NCT05533775Phase 1, Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
United States, Australia, Brazil, China, Czechia +8 more
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT06588855Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
United States, Argentina, Australia, Austria, Belgium +25 more
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruiting
NCT04802759Phase 1, Phase 2Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
United States, Australia, Israel, South Korea, Spain
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruiting
NCT07413939Phase 2, Phase 3Updated Aug 5, 2026
Sponsor: Hoffmann-La Roche
HER2-positive Breast Cancer
United States, Argentina, Australia, Austria, Belgium +18 more
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment DecentralizationRecruiting
NCT07527741N/AUpdated Aug 4, 2026
Sponsor: Hoffmann-La Roche
Early-stage HER2+ Breast Cancer
Serbia
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyRecruiting
NCT05861986Phase 4Updated Aug 4, 2026
Sponsor: Hoffmann-La Roche
Muscular Atrophy, Spinal
United States, Germany, Poland, United Kingdom
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia ARecruiting
NCT07226206Phase 1, Phase 2Updated Aug 4, 2026
Sponsor: Hoffmann-La Roche
Hemophilia A
United States
Cognition Evolution and MRI Markers in PPMS Patients on 2 YearsCompleted
NCT03455582NAUpdated Aug 4, 2026
Sponsor: University Hospital, Bordeaux
Multiple Sclerosis, Primary Progressive
France

Previous page Next page